Evommune completed a phase 2 study of EVO101 in adults with mild to moderate atopic dermatitis.
Evommune has dropped its only clinicalEVO101 asset after reviewing data from atopic dermatitisn atopic dermatitis.
The California-based biotech made the decision to discontinue the interleukin 1 receptor-associaatopic dermatitisK4) inhibitor dubbed EVO101 after considering the results of the midstage study in adults with mild to moderate atopic dermatitis.
IRAK4 continues to be a target of interest for pharma. GileaEVO101nces handed over $20 million upfront in March to license an IRAK4 degrader from Nurix only a month after the Big Pharma dropped two of the three indications being explored for its IRAK4 inhibitor called GS-5718.
IRAK4EVO101 out of the picture, Evommune will “focus itGilead Sciencesadvancing its pipeline of systemically administered prodIRAK4andidates whichNurix multiple milestones expected over the next several years.”IRAK4 inhibitorIRAK4GS-5718
TheseEVO101dates include EVO756,EvommuneRX2 antagonist being developed for urticaria and interstitial cystitis. Evommune said the candidate has the potential to be a first-in-class oral treatment for “a variety of mast cell mediated disease, as well as diseases involving sensory neuron mediated cutaneous itch.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.